Physician profile
Gene Finley
NPI 1730171968
$62,649.66
in general payments reported to CMS, 2019-2025
66 companies · $4,640 in 2025
The $4,640 reported for 2025 was more than what 81% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $3,549 · 2021: $19K · 2022: $14K · 2023: $5,899 · 2024: $3,878 · 2025: $4,640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,750 · Education: $950 · Consulting Fee: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,116.65 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,750.00 |
| Education | $950.13 |
| Consulting Fee | $600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $27,202.64 | 2019-2025 | Tagrisso, Calquence, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $15,074.00 | 2019-2025 | Opdivo, Opdualag |
| F. Hoffmann-La Roche Ag | $6,398.30 | 2019-2021 | |
| Secura Bio, INC. | $1,598.45 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,230.17 | 2020-2025 | |
| Daiichi Sankyo INC. | $948.29 | 2019-2025 | Enhertu, Injectafer, Vanflyta |
| Merck Sharp & Dohme LLC | $866.98 | 2019-2025 | Keytruda, Reblozyl, Lynparza |
| Novartis Pharmaceuticals Corporation | $738.57 | 2023-2025 | |
| Janssen Biotech, INC. | $631.67 | 2022-2025 | Rybrevant, Talvey, Tecvayli |
| Pfizer INC. | $583.68 | 2022-2025 | |
| Astellas Pharma US INC | $575.15 | 2022-2025 | Padcev, Xtandi, Xospata |
| Genentech USA, INC. | $456.03 | 2019-2025 | Venclexta, Polivy, Columvi |
| Incyte Corporation | $426.52 | 2023-2025 | Jakafi, Monjuvi, Pemazyre |
| Regeneron Healthcare Solutions, INC. | $409.49 | 2022-2025 | Libtayo |
| Acrotech Biopharma INC. | $344.85 | 2021-2025 | Beleodaq |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $335.31 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Gilead Sciences, INC. | $269.16 | 2023-2025 | Trodelvy |
| Aveo Pharmaceuticals, INC. | $257.81 | 2024-2025 | |
| Iovance Biotherapeutics, INC. | $244.04 | 2024-2025 | Amtagvi |
| Genzyme Corporation | $241.34 | 2022-2025 | |
| Seagen INC. | $223.92 | 2019-2025 | Padcev, Adcetris |
| Celgene Corporation | $223.25 | 2019-2025 | Opdivo, Reblozyl, Pomalyst |
| Ipsen Biopharmaceuticals, INC | $202.23 | 2022-2025 | Tazverik, Onivyde |
| Novocure INC. | $195.65 | 2020-2025 | Optune Lua (Novottf-200t) |
| Rigel Pharmaceuticals, INC. | $169.92 | 2023-2025 | Rezlidhia, Tavalisse, Gavreto |
| Geron Corporation | $167.74 | 2025 | Rytelo |
| Array Biopharma INC | $159.11 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Apellis Pharmaceuticals, INC. | $146.39 | 2025 | Empaveli |
| Takeda Pharmaceuticals U.S.A., INC. | $144.77 | 2023-2025 | Alunbrig, Ninlaro, Fruzaqla |
| Glaxosmithkline, LLC. | $135.18 | 2024-2025 | Ojjaara, Jemperli, Zejula |
| Genmab U.S., INC. | $133.26 | 2023-2025 | Epkinly |
| Abbvie INC. | $126.92 | 2024-2025 | |
| Eisai INC. | $116.34 | 2023-2024 | |
| Adc Therapeutics America, INC. | $116.16 | 2023-2025 | |
| Pharmaessentia USA Corporation | $113.62 | 2024-2025 | Besremi |
| Sobi, INC | $109.88 | 2023-2024 | |
| Exelixis INC. | $105.79 | 2023-2025 | Cabometyx |
| Kite Pharma, INC. | $103.63 | 2022-2024 | Yescarta |
| Stemline Therapeutics INC. | $103.56 | 2023-2025 | Orserdu |
| Beigene USA, INC. | $97.61 | 2023-2024 | Brukinsa, Tevimbra |
| Sumitomo Pharma America, INC. | $96.56 | 2023-2025 | Orgovyx |
| Alexion Pharmaceuticals, INC. | $87.22 | 2023-2025 | Ultomiris |
| Blueprint Medicines Corporation | $70.60 | 2023-2025 | Ayvakit |
| Beone Medicines USA, INC. | $62.86 | 2025 | Brukinsa, Tevimbra |
| Mirati Therapeutics, INC. | $57.79 | 2023 | Krazati |
| Taiho Oncology, INC. | $56.74 | 2023-2025 | |
| Karyopharm Therapeutics INC. | $56.58 | 2024-2025 | Xpovio |
| Tersera Therapeutics LLC | $42.60 | 2023-2024 | Xermelo |
| Amgen INC. | $35.80 | 2023 | Lumakras, Xgeva, Vectibix |
| Coherus Oncology, INC. | $32.40 | 2025 | Loqtorzi |
| Sun Pharmaceutical Industries INC. | $31.33 | 2025 | |
| Azurity Pharmaceuticals, INC. | $30.80 | 2025 | Danziten |
| Deciphera Pharmaceuticals INC. | $25.59 | 2024 | Qinlock, Tgct |
| Janssen Pharmaceuticals, INC | $25.38 | 2024 | Xarelto |
| Astellas Pharma Global Development | $24.76 | 2023 | Xtandi |
| Caris Mpi, INC. | $22.88 | 2025 | Mi Cancer Seek |
| Emd Serono, INC. | $21.45 | 2025 | |
| Pharmaand Gmbh | $19.26 | 2025 | Rubraca |
| Tolmar, INC. | $19.26 | 2025 | Rubraca, Eligard |
| Kyowa Kirin, INC. | $17.98 | 2024 | Poteligeo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.68 | 2025 | |
| Myovant Sciences INC. | $17.23 | 2022 | |
| Springworks Therapeutics, INC. | $17.11 | 2025 | Ogsiveo |
| Collegium Pharmaceutical, INC. | $16.69 | 2025 | Xtampza |
| Syndax Pharmaceuticals, INC. | $15.73 | 2025 | Revuforj |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5,152.12 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gene Finley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.